AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05576454
Drug: Mepolizumab Injection (EU-licensed Nucala)
RxNorm normalized name: mepolizumab Injection [Nucala]
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (EU-licensed Nucala®).
Trial: NCT05576454
Drug: Mepolizumab Injection (US-licensed Nucala)
RxNorm normalized name: mepolizumab Injection [Nucala]
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In this group, each subject will receive single subcutaneous injection of 100 mg Mepolizumab Injection (US-licensed Nucala®).
Trial: NCT00578825
Drug: Lopinavir / Ritonavir plus Ribavirin
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05641259
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.
Trial: NCT05696691
Drug: Ketamine Hydrochloride
RxNorm normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg IM ketamine to be administered in conjunction with CRP. The ketamine injection will be administered first. Participants will be observed and have vital signs monitored for the first 45 minutes after administering medication in the ED, observing for immediate reactions. Afterwards, participants will continue to be monitored for potential late-term side effects on the inpatient unit. Ketamine will be given only after initial standard of care (SOC) treatment and screening studies have been initiated.
Trial: NCT06667141
Drug: ACR-2316
RxNorm normalized name: ACR-16
DrugBank: ACR-16 (DB05371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACR-2316 is an experimental drug
Trial: NCT05143489
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will receive IV normal saline of 1mg/kg with a max of 40mg
Trial: NCT05945342
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression
Trial: NCT05004727
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab 100 mg 1 mL liquid formulation in a single-dose pre-filled syringe administered by subcutaneous injection at Week 0, Week 4 and every 8 weeks thereafter (month 0 to month 24 for arm 1; week 24 to month 24 for arm 2).
Trial: NCT05945342
Drug: Escitalopram combined with sham rTMS
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication
Trial: NCT00261820
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00261820
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00261820
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00261820
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04916691
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard of care weight-based optimal Ropivacaine dosing for ESPB
Trial: NCT06442111
Drug: The intravenous ferritin group
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer intravenous ferritin approximately 3-7 days before surgery (0.9% normal saline 250ml + 1000 mg of ferric carboxymaltose \[Ferinject™, Vifor Pharma, Glattbrugg, Dwitzerland\], inject over 15 minutes)
Trial: NCT00992472
Drug: Prochlorperazine suppositories, 25mg
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03529539
Drug: PSV
RxNorm normalized name: Mumpsvax
DrugBank: Mumps virus strain B level jeryl lynn live antigen (DB10316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05346419
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received risedronate 35 mg once a week for 6 months.
Trial: NCT05346419
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 2,800 IU of vitamin D once a week, with additional daily supplementation of 4,000 IU of vitamin D
Trial: NCT05541107
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Amphotericin B
Trial: NCT05548270
Drug: DPI-386 Nasal Gel
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will self-administer DPI-386 Nasal Gel or Placebo
Trial: NCT06437522
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT06437522
Drug: PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Trial: NCT05263778
Drug: Bempedoic Acid / Ezetimibe Oral Tablet
RxNorm normalized name: bempedoic acid / ezetimibe Oral Tablet
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bempedoic acid 180 mg/ezetimibe 10 mg by mouth once daily for 12 weeks
Trial: NCT06772857
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin is a drug used to manage blood glucose levels. It improves insulin sensitivity and reduces glucose production in the liver. This regimen will be provided to all study groups (A, B, and C) in combination with the respective interventions described for each group. Participants are instructed not to change their physical activity during the study.
Trial: NCT05559541
Drug: AK119
RxNorm normalized name: AK119
DrugBank: AK119 (DB16423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK119 is an anti-CD73 monoclonal antibody.
Trial: NCT05559541
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.
Trial: NCT06363552
Drug: SC0191 + Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. The SC0191 tablet is taken orally at a dose of 300mg once daily. Each treatment cycle consists of 28 days. Medication is administered on days 1 to 3, days 8 to 10, days 15 to 17, and days 22 to 24 of each cycle.~2. Bevacizumab injection is administered intravenously at a dose of 5mg/kg on day 1 and day 15 of each treatment cycle.
Trial: NCT00089869
Drug: olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00089869
Drug: atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04600323
Drug: Sodium Bicarbonate Tablets
RxNorm normalized name: Sodium Bicarbonate Tablets
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given sodium bicarbonate at 0.5 mEq/kg-LBW/day for 12 months
Trial: NCT04883775
Drug: MVT-2163
RxNorm normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MVT-2163 is administered intravenously as a PET imaging agent.
Trial: NCT04883775
Drug: MVT-5873
RxNorm normalized name: magnesium oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MVT-5873 will be administered intravenously over at least 60 minutes.
Trial: NCT06351332
Drug: Azenosertib
RxNorm normalized name: Azenosertib
DrugBank: Azenosertib (DB18028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEE1 inhibitor, 25 or 100 mg tablet, taken orally per protocol.
Trial: NCT06351332
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Platinum coordination compound, 5-, 15-, 45-, and 60-mL vials, via intravenous (into the vein) infusion per institutional standards.
Trial: NCT06351332
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Humanized immunoglobulin G4 monoclonal antibody, 4-mL vials, via intravenous (into the vein) infusion per protocol.
Trial: NCT00474591
Drug: Fondaparinux
RxNorm normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05767229
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol 0.2 mg/kg for 1.5 hrs
Trial: NCT04970901
Drug: Loncastuximab Tesirine
RxNorm normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion
Trial: NCT04970901
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04970901
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04970901
Drug: Mosunetuzumab
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injection
Trial: NCT04970901
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT05785442
Drug: Anakinra Prefilled Syringe
RxNorm normalized name: anakinra Prefilled Syringe
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 100 mg administration subcutaneously once daily for 10 days (at least 4 days)
Trial: NCT00000856
Drug: Foscarnet sodium
RxNorm normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000856
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05273671
Drug: Nalbuphine
RxNorm normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery
Trial: NCT05273671
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
Trial: NCT05583604
Drug: secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The recommended dose is 300 mg of secukinumab by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4, followed by a maintenance dose of 300 mg every 2 weeks. Each 300 mg dose is given as one subcutaneous injection of 300 mg or as two subcutaneous injections of 150 mg.
Trial: NCT05959356
Drug: Cetuximab + Envafolimab + mFOLFOXIRI
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 500mg/m² + envafolimab 200mg + irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + envafolimab 200mg + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
Trial: NCT05959356
Drug: Cetuximab + mFOLFOX6/FOLFIRI
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 500mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h or cetuximab 500mg/m² + irinotecan 180 mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle up to max 8 cycles, followed by maintenance with cetuximab 500mg/m² + leucovorin 200 mg/m² + 5-FU 2400 mg/m² civ. 46h all on day 1 of each 2 weeks cycle until PD, unacceptable toxicity or patient's refusal.
Trial: NCT05838118
Drug: Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologically active human fecal fluid (donor stool) is provided in fluid form.
Trial: NCT06032845
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a PD-1 immune check inhibitor
Trial: NCT06032845
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib capsules
Trial: NCT06035497
Drug: BMS-986369
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06722950
Drug: AC591
RxNorm normalized name: Acetaminophen and Codeine Phosphate
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC591 : 3 times a day (daily), taken with boiled water.
Trial: NCT05793268
Drug: Entecavir or Tenofovir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of either entecavir or tenofovir treatment for 3 years
Trial: NCT06722963
Drug: Nalbuphine
RxNorm normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nalbuphine in doses ranging from 10 mg have been studied as adjuvants to bupivacaine
Trial: NCT06723964
Drug: AP505
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: AP505 is a Anti-PD-L1 and Anti-VEGF Antibody Fusion Protein.
Trial: NCT06441916
Drug: Dabigatran Etexilate Capsules 150 mg
RxNorm normalized name: dabigatran etexilate 150 MG
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran Etexilate
Trial: NCT05147090
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 10mg daily
Trial: NCT05965544
Drug: Bupivacain (preoperative)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the patients are in the supine position and aseptic conditions are provided in the preoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
Trial: NCT05965544
Drug: Bupivacaine-fentanyl
RxNorm normalized name: Bupivacaine-Fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will be placed in the lateral decubitus position with the fractured side up. After the spinal anesthesia method was provided with aseptic conditions, 10 mg 0.5% bupivacaine + 20 mcg Fentanyl injection will be applied using a 26 Gauge pencil point needle through the L3-L4 or L4-L5 intervertebral space
Trial: NCT05965544
Drug: Bupivacain (Postoperative)
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the patients are in the supine position and aseptic conditions are provided in the postoperative period, the fascia on the iliacus muscle will be determined with the help of an 8-12 MHz linear probe and a block will be applied with the in-plane technique. During the block, 0.2% bupivacaine concentration 0.5 mL/kg is routinely used in patients.
Trial: NCT05912192
Drug: Elonide Nasal Spray
RxNorm normalized name: Desonide
DrugBank: Desonide (DB01260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mcg/dose One puff for each nostrils twice daily
Trial: NCT05912192
Drug: Nasonex Nasal Spray
RxNorm normalized name: mometasone Metered Dose Nasal Spray [Nasonex]
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mcg/dose One puff for each nostrils twice daily
Trial: NCT06371040
Drug: CD19-BCMA Targeted CAR-T Dose 1
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 e5/ kg CD19-BCMA CAR-T positive T cells
Trial: NCT06371040
Drug: CD19-BCMA Targeted CAR-T Dose 2
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 e6/ kg CD19-BCMA CAR-T positive T cells
Trial: NCT06371040
Drug: CD19-BCMA Targeted CAR-T Dose 2
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 e6/ kg CD19-BCMA CAR-T positive T cells
Trial: NCT04667052
Drug: JNJ 64304500
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single subcutaneous dose of JNJ-64304500 reference formulation.
Trial: NCT04667052
Drug: JNJ 64304500
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single subcutaneous dose of JNJ-64304500 test formulation.
Trial: NCT00000172
Drug: Galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04612712
Drug: Donafenib Tosilate Tablets
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the dose exploration phase (phase I) : three doses of Donafenib tosylate tablets \[50 mg twice a day; 100 mg twice a day; 200 mg twice a day \] will be explored. In the dose expansion phase (phase II), patients with advanced hepatocellular carcinoma will be treated at the recommended dose for phase 2(RP2D).The RP2D will be determined by the dose escalation study.
Trial: NCT05753696
Drug: Azilsartan
RxNorm normalized name: Azilsartan
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan initial dose 20mg/d, if not reached the goal of hypertension; azilsartan dose 40mg/d
Trial: NCT05753696
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: losartan initial dose 40mg/d, if not reached the goal of hypertension; losartan 100mg/d
Trial: NCT00246675
Drug: Frusemide
RxNorm normalized name: Frusemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04888507
Drug: Pozelimab
RxNorm normalized name: Pozelimab
DrugBank: Pozelimab (DB15218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration
Trial: NCT05302726
Drug: Estrogen
RxNorm normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal and oral estrogen both as substitution therapy
Trial: NCT04888507
Drug: Cemdisiran
RxNorm normalized name: Cemdisiran
DrugBank: Cemdisiran (DB16121)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC administration
Trial: NCT05649709
Drug: L-VA dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
Trial: NCT05649709
Drug: H-VA dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
Trial: NCT04856488
Drug: Iodine-Potassium Iodide 5%-10% Oral and Topical Solution
RxNorm normalized name: iodine-potassium iodide 5%-10% oral and topical solution
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine Potassium Iodide 5% oral solution, administered 3 times per day for 10 days
Trial: NCT04657861
Drug: APRIL CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive APRIL CAR T-cells by intravenous infusion
Trial: NCT06266832
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 20mg/kg, administered every 3 Weeks (Q3W).
Trial: NCT06266832
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130mg/m2, ivgtt, d1, Q3W
Trial: NCT04355039
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg Days 1-21
Trial: NCT04355039
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg Days 1, 8, 15 and 22
Trial: NCT04355039
Drug: INCB053914 50 mg bis in die (BID)
RxNorm normalized name: bis-hydroxyethoxypropyl dimethicone (50 CST)
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 0: 50 mg BID
Trial: NCT04355039
Drug: INCB053914 65 mg BID
RxNorm normalized name: INCB053914
DrugBank: Uzansertib (DB17571)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1: 65 mg BID